相关实验视频
Updated: Jul 1, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在第三级医院的2型糖尿病患者中评估静止素指示和剂量强化
Pineal Yitbarek Fisseha1, Assefa Mulu Baye2, Melak Gedamu Beyene2
1Tikur Anbessa Specialized Hospital, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
概括
对于大多数2型糖尿病患者来说,他类药物治疗是合适的,超过三分之二的患者接受了正确的剂量强化. 然而,需要仔细监测,以防止在某些患者群体中不适当的他类药物强化.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病 (DM) 显著增加了心血管疾病 (CVD) 的风险.
- 准则建议在2型糖尿病 (T2DM) 中使用他类药物治疗,以减少心血管疾病事件和死亡率.
- 开始服用他类药物和调整剂量的挑战会影响T2DM患者的治疗结果.
研究的目的:
- 评估在T2DM患者中使用他类药物的适宜性.
- 在T2DM患者中评估他类药物剂量强化策略的准确性.
- 确定影响T2DM中他类药物治疗适宜性的因素.
主要方法:
- 一项基于医院的横截面研究,涉及405名T2DM患者.
- 系统的随机抽样被用于患者的选择.
- 统计分析包括调整的几率比率 (AOR) 与95%的置信区间 (CI).
主要成果:
- 对于96.2%的患者来说,他类药物适用于初级或二级心血管疾病预防.
- 在62.4%的T2DM患者中,剂量强化是适当的.
- 与不适当的他类药物强化相关的因素包括糖尿病持续时间较长,男性性别,年龄较大和失控的血压.
结论:
- 在T2DM患者中,静止剂治疗的指示通常是最佳的.
- 大约三分之二的T2DM患者经历了适当的他类药物剂量强化.
- 加强监测至关重要,以防止不适当的他类药物强化,特别是在高风险的T2DM子组.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:16Insulin: Dosing Regimen and Adverse Effects
170
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
170
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
01:23Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
01:15Diabetes: Management and Pharmacotherapy
282
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
282
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K